Efnisyfirlit

• Cover image
• Title page
• Table of Contents
• Copyright
• Foreword
• About the Author
• Preface
• Part 1: The Science of Health
• Introduction
• Chapter 1: The Origins of Health
• Abstract
• 1.1 What is Health?
• 1.2 What Makes Humans Healthy?
• 1.3 Historical Causes of Increased Life Expectancy
• Chapter 2: Current Patterns of Death and Disease
• Abstract
• 2.1 Current Main Causes of Death
• 2.2 Habits and Habitats Ancient and Modern
• 2.3 Discordance Between Paleolithic and Modern Habits and Habitats
• 2.4 What Is Healthcare For? The Preeminence of Behavioral Outcomes
• Chapter 3: Twelve Millennia of Changing Human Habits and Habitats
• Abstract
• 3.1 Epidemiologic Transition
• 3.2 Demographic Transition
• 3.3 Transitions in Transition
• 3.4 What Longevity Revolution?
• 3.5 Are Populations Healthier Now As Well As Longer Lived?
• 3.6 Morbidity: Compression, Expansion, or Equilibrium?
• Chapter 4: Biomedicine and Common Causes of Mortality and Morbidity
• Abstract
• 4.1 Road Traffic Injury and Biomedicine: The Relevance of Policy
• 4.2 Cardiovascular Disease: The Leading Global Cause of Mortality and Morbidity
• Part 2: The Harm of Medicine
• Introduction
• What about the Good of Medicine?
• Chapter 5: Medical Harm: What Is It and What Is the Extent?
• Abstract
• 5.1 Medical Harm: What Is It?
• 5.2 Serial Harm: Wayward Doctors and Malfunctioning Systems
• 5.3 To Err Is Human: Harm Caused in the Routine Practice of Medicine
• 5.4 To Err Is Human, but to Repeat the Error Is…Inevitable!
• 5.5 Is Medicine Safe? Is It Getting Safer? The Evidence Says “No” to Both Questions
• 5.6 Can Biomedical Healthcare Be Made Safe?
• Chapter 6: Sources of Harm: Prescription Drugs, Surgery, and Infections
• Abstract
• 6.1 Harm from Prescription Drugs
• 6.2 Harm from Surgery
• 6.3 Healthcare-Associated Infection
• 6.4 Multiple Drug Resistance
• 6.5 Limiting Harm Due to Antibiotic Resistance
• Chapter 7: The Commercial Culture of Medicine
• Abstract
• 7.1 The Myth of Safe and Effective Prescription Drugs
• 7.2 Has Medicine Sold Out to Big Pharma?
• 7.3 What Doctors Do (and Don’t Do) to Limit Harmful Commercialism in Clinical Practice
• Chapter 8: Big Pharma Entanglement with Biomedical Science
• Abstract
• 8.1 Science in the Service of Industry: The Loss of Scientific Integrity in Biomedical Research
• 8.2 Partners in Crime
• 8.3 Manufacturing Bias in Scientific Research
• 8.4 Disclosure of Conflicts of Interest in Biomedical Research
• Chapter 9: The Charms and Harms of Personalized Medicine
• Abstract
• 9.1 Why Is Genomic Medicine Said to Be Personalized?
• 9.2 What Is the Efficacy of Personalized Medicine Now and What Is It Likely to Be?
• 9.3 To Screen or Not to Screen? Why Is That a Question?
• 9.4 The Genome Is but One Piece of the Heterogeneous Mosaic of Life
• 9.5 Genomic Personalized Medicine: Future Prospects and Legacy
• Part 3: Achieving Optimal Health Sustainably
• Introduction
• Chapter 10: Healing Practices and Evidence-Based Medicine
• Abstract
• 10.1 The Nature of Healing
• 10.2 Evidence-Based Medicine
• 10.3 Unwelcome Discoveries: Established Interventions That Don’t Work
• Chapter 11: Placebo and the Therapeutic Process
• Abstract
• 11.1 The Placebo: Powerful, Powerless, or Passé?
• 11.2 The Therapeutic Process
• 11.3 Why Do Practitioners Use Interventions That Have No Specific Benefit?
• Chapter 12: Prevention and Control of Disease
• Abstract
• 12.1 The Power of Prevention: Reorienting Healthcare
• Chapter 13: Associated Prevention Concepts and Models
• Abstract
• 13.1 Ecological Models of Health and the Emergence of Health Activism
• 13.2 Health Inequality and the Social Determinants of Health
• 13.3 Health in All Policies
• 13.4 Welfare Provision and the “Nanny” State: Nudge, Fudge, Smudge, Grudge, or Budge
• 13.5 Why Do Successes in Prevention Not Attract the Accolades They Deserve?
• 13.6 Why Has Healthcare Not Adopted Prevention as the Predominant Approach?
• 13.7 What About the Ethical Imperative of Providing Help for Suffering Individuals?
• 13.8 The Ethical Foundations of Prevention Over Cure
• Chapter 14: Optimal Healthcare: Risk Factor Reduction and Adjunctive Biomedical Intervention
• Abstract
• 14.1 Program for Prevention and Control of Common Complex Diseases Incorporating Risk Factor Reduction and Adjunctive Biomedical Care
• 14.2 Prevention of Disease Through Risk Factor Reduction to Reduce Disease Incidence
• 14.3 Biomedical Intervention to Control Disease Progression
• Chapter 15: Mental Health
• Abstract
• 15.1 Mental Disorder: The Triple Yoke of Big Pharma, Psychiatry, and the Biomedical Model
• 15.2 Psychosocial Mental Health Promotion, Prevention, and Intervention
• Epilogue
• List of Acronyms
• Glossary
• Subject Index
• Author Index